These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
362 related articles for article (PubMed ID: 20096354)
21. Understanding the poor iontophoretic transport of lysozyme across the skin: when high charge and high electrophoretic mobility are not enough. Dubey S; Kalia YN J Control Release; 2014 Jun; 183():35-42. PubMed ID: 24657950 [TBL] [Abstract][Full Text] [Related]
22. Transdermal iontophoretic delivery of triptorelin in vitro. Schuetz YB; Naik A; Guy RH; Vuaridel E; Kalia YN J Pharm Sci; 2005 Oct; 94(10):2175-82. PubMed ID: 16136544 [TBL] [Abstract][Full Text] [Related]
23. Effect of iontophoresis on in vitro transdermal absorption of almotriptan. Calatayud-Pascual MA; Balaguer-Fernández C; Serna-Jiménez CE; Del Rio-Sancho S; Femenía-Font A; Merino V; López-Castellano A Int J Pharm; 2011 Sep; 416(1):189-94. PubMed ID: 21736929 [TBL] [Abstract][Full Text] [Related]
24. Granisetron transdermal system: a new option to help prevent chemotherapy-induced nausea and vomiting. Schulmeister L Clin J Oncol Nurs; 2009 Dec; 13(6):711-4. PubMed ID: 19948469 [TBL] [Abstract][Full Text] [Related]
25. Dermal, subdermal, and systemic concentrations of granisetron by iontophoretic delivery. Chaturvedula A; Joshi DP; Anderson C; Morris R; Sembrowich WL; Banga AK Pharm Res; 2005 Aug; 22(8):1313-9. PubMed ID: 16078141 [TBL] [Abstract][Full Text] [Related]
26. Combined effects of iontophoretic and chemical enhancement on drug delivery. II. Transport across human and murine skin. Nolan LM; Corish J; Corrigan OI; Fitzpatrick D Int J Pharm; 2007 Aug; 341(1-2):114-24. PubMed ID: 17502130 [TBL] [Abstract][Full Text] [Related]
27. Contributions of electromigration and electroosmosis to peptide iontophoresis across intact and impaired skin. Abla N; Naik A; Guy RH; Kalia YN J Control Release; 2005 Nov; 108(2-3):319-30. PubMed ID: 16169627 [TBL] [Abstract][Full Text] [Related]
28. Transdermal iontophoresis of the dopamine agonist 5-OH-DPAT in human skin in vitro. Nugroho AK; Li L; Dijkstra D; Wikström H; Danhof M; Bouwstra JA J Control Release; 2005 Mar; 103(2):393-403. PubMed ID: 15763622 [TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics of a granisetron transdermal system for the treatment of chemotherapy-induced nausea and vomiting. Howell J; Smeets J; Drenth HJ; Gill D J Oncol Pharm Pract; 2009 Dec; 15(4):223-31. PubMed ID: 19304880 [TBL] [Abstract][Full Text] [Related]
30. Effect of controlled laser microporation on drug transport kinetics into and across the skin. Bachhav YG; Summer S; Heinrich A; Bragagna T; Böhler C; Kalia YN J Control Release; 2010 Aug; 146(1):31-6. PubMed ID: 20678988 [TBL] [Abstract][Full Text] [Related]
31. Synergistic effect of iontophoresis and soluble microneedles for transdermal delivery of methotrexate. Vemulapalli V; Yang Y; Friden PM; Banga AK J Pharm Pharmacol; 2008 Jan; 60(1):27-33. PubMed ID: 18088502 [TBL] [Abstract][Full Text] [Related]
32. Transdermal iontophoretic delivery of terbinafine hydrochloride: quantitation of drug levels in stratum corneum and underlying skin. Sachdeva V; Siddoju S; Yu YY; Kim HD; Friden PM; Banga AK Int J Pharm; 2010 Mar; 388(1-2):24-31. PubMed ID: 20025950 [TBL] [Abstract][Full Text] [Related]
33. Cutaneous iontophoretic delivery of CGP69669A, a sialyl Lewis(x) mimetic, in vitro. Gratieri T; Wagner B; Kalaria D; Ernst B; Kalia YN Exp Dermatol; 2012 Mar; 21(3):226-8. PubMed ID: 22379971 [TBL] [Abstract][Full Text] [Related]
34. Transcorneal iontophoresis for delivery of ciprofloxacin hydrochloride. Vaka SR; Sammeta SM; Day LB; Murthy SN Curr Eye Res; 2008 Aug; 33(8):661-7. PubMed ID: 18696341 [TBL] [Abstract][Full Text] [Related]
35. Effect of permeation enhancers on the iontophoretic transport of metoprolol tartrate and the drug retention in skin. Nair A; Vyas H; Shah J; Kumar A Drug Deliv; 2011 Jan; 18(1):19-25. PubMed ID: 20726811 [TBL] [Abstract][Full Text] [Related]
36. Facilitated skin penetration of lidocaine: combination of a short-term iontophoresis and microemulsion formulation. Sintov AC; Brandys-Sitton R Int J Pharm; 2006 Jun; 316(1-2):58-67. PubMed ID: 16564144 [TBL] [Abstract][Full Text] [Related]
37. Heterogeneity in systemic availability of ondansetron and granisetron following oral administration. Corrigan BW; Nicholls B; Thakrar B; Lam R; Grosse C; Alianti J; Palmer JL Drug Metab Dispos; 1999 Jan; 27(1):110-2. PubMed ID: 9884318 [TBL] [Abstract][Full Text] [Related]
38. Simultaneous controlled iontophoretic delivery of pramipexole and rasagiline in vitro and in vivo: Transdermal polypharmacy to treat Parkinson's disease. Kalaria DR; Singhal M; Patravale V; Merino V; Kalia YN Eur J Pharm Biopharm; 2018 Jun; 127():204-212. PubMed ID: 29477356 [TBL] [Abstract][Full Text] [Related]
39. Transdermal iontophoresis of insulin: III. Influence of electronic parameters. Pillai O; Kumar N; Dey CS; Borkute ; Sivaprasad N; Panchagnula R Methods Find Exp Clin Pharmacol; 2004; 26(6):399-408. PubMed ID: 15349135 [TBL] [Abstract][Full Text] [Related]
40. The in vitro and in vivo evaluation of new synthesized prodrugs of 5-OH-DPAT for iontophoretic delivery. Ackaert OW; De Graan J; Capancioni R; Della Pasqua OE; Dijkstra D; Westerink BH; Danhof M; Bouwstra JA J Control Release; 2010 Jun; 144(3):296-305. PubMed ID: 20230864 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]